Race and Fistulizing Perianal Crohn’s Disease
BACKGROUND:There is increasing recognition of Crohn’s disease (CD) in non-white populations. However, reports of racial disparities in the phenotype of CD are still inconsistent. AIM:The aim of this study was to test the hypothesis that African American (AA) patients have higher incidence of severe...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical gastroenterology 2015-03, Vol.49 (3), p.e21-e23 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e23 |
|---|---|
| container_issue | 3 |
| container_start_page | e21 |
| container_title | Journal of clinical gastroenterology |
| container_volume | 49 |
| creator | Alli-Akintade, Latifat Pruthvi, Patel Hadi, Nicole Sachar, David |
| description | BACKGROUND:There is increasing recognition of Crohn’s disease (CD) in non-white populations. However, reports of racial disparities in the phenotype of CD are still inconsistent.
AIM:The aim of this study was to test the hypothesis that African American (AA) patients have higher incidence of severe fistulizing perianal Crohn’s disease (FPD) compared with white patients.
METHODS:Cross-sectional analysis of 333 adult CD patients treated at The Mount Sinai Hospital with infliximab between May 2011 and December 2011 was conducted. Self-reported race/ethnicity was recorded and proportions of each group with FPD were compared across the population.
RESULTS:Among all 333 evaluable CD patients on infliximab, 73.6% were white, 11.4% AA, 13.2% Hispanic, and 1.8% Asian. Of these 333 patients, 88 had FPDonly 48 of these (54.5%) were white, whereas fully 18 (20.5%) were AA, 20 (22.7%) were Hispanic, and 2 (2.3%) were Asian. Thus, patients receiving infliximab for FPD were significantly more likely to be AA or Hispanic than white (AA vs. whitesrisk ratio=2.63; 95% confidence interval, 1.74-3.96; P= |
| doi_str_mv | 10.1097/MCG.0000000000000117 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1652458654</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1652458654</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4267-c6eef50d495fde675b62a7665e51c6ee33d7c43e7c50c2723a272fd120546b493</originalsourceid><addsrcrecordid>eNp9kM9Kw0AQhxdRbK2-gUiOXtLu_22OEm0VKoroedlsJja6TepuQtGTr-Hr-SSmtIp4cA4zh_l-M_AhdEzwkOBEja7T6RD_LkLUDuoTwZKYYkZ2UR-ThMZYJbiHDkJ46hDFGNlHPcrHIlGE9dHozliITJVHkzI0rSvfyuoxugVfmsq4KPX1vPp8_wjReRnABDhEe4VxAY62c4AeJhf36WU8u5lepWez2HIqVWwlQCFwzhNR5CCVyCQ1SkoBgqx3jOXKcgbKCmyposx0rcgJxYLLjCdsgE43d5e-fmkhNHpRBgvOmQrqNmgiBeViLAXvUL5Bra9D8FDopS8Xxr9qgvVale5U6b-qutjJ9kObLSD_CX276YDxBljVrgEfnl27Aq_nYFwz___2F_noc6Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1652458654</pqid></control><display><type>article</type><title>Race and Fistulizing Perianal Crohn’s Disease</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Alli-Akintade, Latifat ; Pruthvi, Patel ; Hadi, Nicole ; Sachar, David</creator><creatorcontrib>Alli-Akintade, Latifat ; Pruthvi, Patel ; Hadi, Nicole ; Sachar, David</creatorcontrib><description>BACKGROUND:There is increasing recognition of Crohn’s disease (CD) in non-white populations. However, reports of racial disparities in the phenotype of CD are still inconsistent.
AIM:The aim of this study was to test the hypothesis that African American (AA) patients have higher incidence of severe fistulizing perianal Crohn’s disease (FPD) compared with white patients.
METHODS:Cross-sectional analysis of 333 adult CD patients treated at The Mount Sinai Hospital with infliximab between May 2011 and December 2011 was conducted. Self-reported race/ethnicity was recorded and proportions of each group with FPD were compared across the population.
RESULTS:Among all 333 evaluable CD patients on infliximab, 73.6% were white, 11.4% AA, 13.2% Hispanic, and 1.8% Asian. Of these 333 patients, 88 had FPDonly 48 of these (54.5%) were white, whereas fully 18 (20.5%) were AA, 20 (22.7%) were Hispanic, and 2 (2.3%) were Asian. Thus, patients receiving infliximab for FPD were significantly more likely to be AA or Hispanic than white (AA vs. whitesrisk ratio=2.63; 95% confidence interval, 1.74-3.96; P=<0.0001; Hispanics vs. whitesrisk ratio=2.32; 95% confidence interval, 1.54-3.50; P=0.0001). There was no statistically significant difference between AA and Hispanics.
CONCLUSION:CD patients at our medical center with FPD requiring infliximab therapy were significantly more likely to be AA or Hispanic.</description><identifier>ISSN: 0192-0790</identifier><identifier>EISSN: 1539-2031</identifier><identifier>DOI: 10.1097/MCG.0000000000000117</identifier><identifier>PMID: 24859713</identifier><language>eng</language><publisher>United States: Copyright Wolters Kluwer Health, Inc. All rights reserved</publisher><subject>African Americans ; Anti-Inflammatory Agents - therapeutic use ; Antibodies, Monoclonal - therapeutic use ; Asian Americans ; Chi-Square Distribution ; Crohn Disease - diagnosis ; Crohn Disease - drug therapy ; Crohn Disease - ethnology ; Cross-Sectional Studies ; European Continental Ancestry Group ; Gastrointestinal Agents - therapeutic use ; Hispanic Americans ; Humans ; Incidence ; Infliximab ; New York City - epidemiology ; Odds Ratio ; Phenotype ; Prevalence ; Rectal Fistula - diagnosis ; Rectal Fistula - drug therapy ; Rectal Fistula - ethnology ; Risk Factors ; Severity of Illness Index ; Tertiary Care Centers ; Urban Health</subject><ispartof>Journal of clinical gastroenterology, 2015-03, Vol.49 (3), p.e21-e23</ispartof><rights>Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4267-c6eef50d495fde675b62a7665e51c6ee33d7c43e7c50c2723a272fd120546b493</citedby><cites>FETCH-LOGICAL-c4267-c6eef50d495fde675b62a7665e51c6ee33d7c43e7c50c2723a272fd120546b493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24859713$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alli-Akintade, Latifat</creatorcontrib><creatorcontrib>Pruthvi, Patel</creatorcontrib><creatorcontrib>Hadi, Nicole</creatorcontrib><creatorcontrib>Sachar, David</creatorcontrib><title>Race and Fistulizing Perianal Crohn’s Disease</title><title>Journal of clinical gastroenterology</title><addtitle>J Clin Gastroenterol</addtitle><description>BACKGROUND:There is increasing recognition of Crohn’s disease (CD) in non-white populations. However, reports of racial disparities in the phenotype of CD are still inconsistent.
AIM:The aim of this study was to test the hypothesis that African American (AA) patients have higher incidence of severe fistulizing perianal Crohn’s disease (FPD) compared with white patients.
METHODS:Cross-sectional analysis of 333 adult CD patients treated at The Mount Sinai Hospital with infliximab between May 2011 and December 2011 was conducted. Self-reported race/ethnicity was recorded and proportions of each group with FPD were compared across the population.
RESULTS:Among all 333 evaluable CD patients on infliximab, 73.6% were white, 11.4% AA, 13.2% Hispanic, and 1.8% Asian. Of these 333 patients, 88 had FPDonly 48 of these (54.5%) were white, whereas fully 18 (20.5%) were AA, 20 (22.7%) were Hispanic, and 2 (2.3%) were Asian. Thus, patients receiving infliximab for FPD were significantly more likely to be AA or Hispanic than white (AA vs. whitesrisk ratio=2.63; 95% confidence interval, 1.74-3.96; P=<0.0001; Hispanics vs. whitesrisk ratio=2.32; 95% confidence interval, 1.54-3.50; P=0.0001). There was no statistically significant difference between AA and Hispanics.
CONCLUSION:CD patients at our medical center with FPD requiring infliximab therapy were significantly more likely to be AA or Hispanic.</description><subject>African Americans</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Asian Americans</subject><subject>Chi-Square Distribution</subject><subject>Crohn Disease - diagnosis</subject><subject>Crohn Disease - drug therapy</subject><subject>Crohn Disease - ethnology</subject><subject>Cross-Sectional Studies</subject><subject>European Continental Ancestry Group</subject><subject>Gastrointestinal Agents - therapeutic use</subject><subject>Hispanic Americans</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infliximab</subject><subject>New York City - epidemiology</subject><subject>Odds Ratio</subject><subject>Phenotype</subject><subject>Prevalence</subject><subject>Rectal Fistula - diagnosis</subject><subject>Rectal Fistula - drug therapy</subject><subject>Rectal Fistula - ethnology</subject><subject>Risk Factors</subject><subject>Severity of Illness Index</subject><subject>Tertiary Care Centers</subject><subject>Urban Health</subject><issn>0192-0790</issn><issn>1539-2031</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM9Kw0AQhxdRbK2-gUiOXtLu_22OEm0VKoroedlsJja6TepuQtGTr-Hr-SSmtIp4cA4zh_l-M_AhdEzwkOBEja7T6RD_LkLUDuoTwZKYYkZ2UR-ThMZYJbiHDkJ46hDFGNlHPcrHIlGE9dHozliITJVHkzI0rSvfyuoxugVfmsq4KPX1vPp8_wjReRnABDhEe4VxAY62c4AeJhf36WU8u5lepWez2HIqVWwlQCFwzhNR5CCVyCQ1SkoBgqx3jOXKcgbKCmyposx0rcgJxYLLjCdsgE43d5e-fmkhNHpRBgvOmQrqNmgiBeViLAXvUL5Bra9D8FDopS8Xxr9qgvVale5U6b-qutjJ9kObLSD_CX276YDxBljVrgEfnl27Aq_nYFwz___2F_noc6Y</recordid><startdate>201503</startdate><enddate>201503</enddate><creator>Alli-Akintade, Latifat</creator><creator>Pruthvi, Patel</creator><creator>Hadi, Nicole</creator><creator>Sachar, David</creator><general>Copyright Wolters Kluwer Health, Inc. All rights reserved</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201503</creationdate><title>Race and Fistulizing Perianal Crohn’s Disease</title><author>Alli-Akintade, Latifat ; Pruthvi, Patel ; Hadi, Nicole ; Sachar, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4267-c6eef50d495fde675b62a7665e51c6ee33d7c43e7c50c2723a272fd120546b493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>African Americans</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Asian Americans</topic><topic>Chi-Square Distribution</topic><topic>Crohn Disease - diagnosis</topic><topic>Crohn Disease - drug therapy</topic><topic>Crohn Disease - ethnology</topic><topic>Cross-Sectional Studies</topic><topic>European Continental Ancestry Group</topic><topic>Gastrointestinal Agents - therapeutic use</topic><topic>Hispanic Americans</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infliximab</topic><topic>New York City - epidemiology</topic><topic>Odds Ratio</topic><topic>Phenotype</topic><topic>Prevalence</topic><topic>Rectal Fistula - diagnosis</topic><topic>Rectal Fistula - drug therapy</topic><topic>Rectal Fistula - ethnology</topic><topic>Risk Factors</topic><topic>Severity of Illness Index</topic><topic>Tertiary Care Centers</topic><topic>Urban Health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alli-Akintade, Latifat</creatorcontrib><creatorcontrib>Pruthvi, Patel</creatorcontrib><creatorcontrib>Hadi, Nicole</creatorcontrib><creatorcontrib>Sachar, David</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alli-Akintade, Latifat</au><au>Pruthvi, Patel</au><au>Hadi, Nicole</au><au>Sachar, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Race and Fistulizing Perianal Crohn’s Disease</atitle><jtitle>Journal of clinical gastroenterology</jtitle><addtitle>J Clin Gastroenterol</addtitle><date>2015-03</date><risdate>2015</risdate><volume>49</volume><issue>3</issue><spage>e21</spage><epage>e23</epage><pages>e21-e23</pages><issn>0192-0790</issn><eissn>1539-2031</eissn><abstract>BACKGROUND:There is increasing recognition of Crohn’s disease (CD) in non-white populations. However, reports of racial disparities in the phenotype of CD are still inconsistent.
AIM:The aim of this study was to test the hypothesis that African American (AA) patients have higher incidence of severe fistulizing perianal Crohn’s disease (FPD) compared with white patients.
METHODS:Cross-sectional analysis of 333 adult CD patients treated at The Mount Sinai Hospital with infliximab between May 2011 and December 2011 was conducted. Self-reported race/ethnicity was recorded and proportions of each group with FPD were compared across the population.
RESULTS:Among all 333 evaluable CD patients on infliximab, 73.6% were white, 11.4% AA, 13.2% Hispanic, and 1.8% Asian. Of these 333 patients, 88 had FPDonly 48 of these (54.5%) were white, whereas fully 18 (20.5%) were AA, 20 (22.7%) were Hispanic, and 2 (2.3%) were Asian. Thus, patients receiving infliximab for FPD were significantly more likely to be AA or Hispanic than white (AA vs. whitesrisk ratio=2.63; 95% confidence interval, 1.74-3.96; P=<0.0001; Hispanics vs. whitesrisk ratio=2.32; 95% confidence interval, 1.54-3.50; P=0.0001). There was no statistically significant difference between AA and Hispanics.
CONCLUSION:CD patients at our medical center with FPD requiring infliximab therapy were significantly more likely to be AA or Hispanic.</abstract><cop>United States</cop><pub>Copyright Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>24859713</pmid><doi>10.1097/MCG.0000000000000117</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0192-0790 |
| ispartof | Journal of clinical gastroenterology, 2015-03, Vol.49 (3), p.e21-e23 |
| issn | 0192-0790 1539-2031 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1652458654 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | African Americans Anti-Inflammatory Agents - therapeutic use Antibodies, Monoclonal - therapeutic use Asian Americans Chi-Square Distribution Crohn Disease - diagnosis Crohn Disease - drug therapy Crohn Disease - ethnology Cross-Sectional Studies European Continental Ancestry Group Gastrointestinal Agents - therapeutic use Hispanic Americans Humans Incidence Infliximab New York City - epidemiology Odds Ratio Phenotype Prevalence Rectal Fistula - diagnosis Rectal Fistula - drug therapy Rectal Fistula - ethnology Risk Factors Severity of Illness Index Tertiary Care Centers Urban Health |
| title | Race and Fistulizing Perianal Crohn’s Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T08%3A09%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Race%20and%20Fistulizing%20Perianal%20Crohn%E2%80%99s%20Disease&rft.jtitle=Journal%20of%20clinical%20gastroenterology&rft.au=Alli-Akintade,%20Latifat&rft.date=2015-03&rft.volume=49&rft.issue=3&rft.spage=e21&rft.epage=e23&rft.pages=e21-e23&rft.issn=0192-0790&rft.eissn=1539-2031&rft_id=info:doi/10.1097/MCG.0000000000000117&rft_dat=%3Cproquest_cross%3E1652458654%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1652458654&rft_id=info:pmid/24859713&rfr_iscdi=true |